OncoDNA is a company specializing in precision medicine for the treatment of cancer and other genetic diseases. We are a group of passionate people who have developed a unique portfiolio of smart and personalized solutions to help you see clear through molecular complexity. You can rely on our extensive expertise in genomics and theranostics to collect, explore and interpret the tons of complex data that you need for your research project, clinical trials or clinical decision-making. Together, we can bring therapeutic innovation to the clinics and deliver the best of care to patients.
We are dedicated to helping you drive innovation in cancer and genetic diseases. Through a variety of NGS, molecular profiling and bioinformatics services, we can deliver the robust, accurate and reliable data that you need to conduct research projects in a rapid and cost-efficient manner.
Treating advanced cancer or cancer of unknown primary can be challenging. Our biomarker testing solutions are designed to help you spot the molecular weaknesses of a solid tumor, predict resistance to cancer therapies, identify the most effective cancer treatment options and monitor your patient's response to therapy in real time.
Our oncology biomarker tests help to better understand the molecular complexity of solid tumors. They use next-generation sequencing and advanced bioinformatics to collect powerful data and turn them into strategies. They can inform the selection of the most effective cancer treatment options (including chemotherapy, immunotherapy, targeted therapy, hormone therapy or clinical trials) for patients diagnosed with an advanced solid tumor, and support the close monitoring of patient response to treatment.
We offer a broad variety of NGS services to support the progress of your research. Our genomic services are performed by IntegraGen, an OncoDNA group company specializing in the genomics of cancer and genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in next-generation sequencing which has been operating sequencing platforms for research institutes of excellence for over 10 years.
Exome, whole genome and custom gene panel sequencing services for cancer and rare diseases.
Cost-effective and high-throughput services to analyze genome-wide methylation profiles.
RNA sequencing services to precisely measure gene expression signatures in tissue samples or liquid biopsies.
Cost-effective and flexible services to interrogate 10’s to millions SNP markers in a timely manner.
Our tumor profiling kits are designed to help laboratories to adopt comprehensive tissue-based biomarker testing in-house. The kits offer a complete workflow solution to screen a tumor tissue for hundreds of biomarkers associated with precision medicines and to analyze the data in full autonomy. Even laboratories with limited bioinformatics capabilities will have all the tools required to advise oncologists in the selection of the most effective and personalized treatments for their cancer patients.
We have developed a complete portfolio of secure online platforms to help you analyze your sequencing data quickly and easily, match them with the latest therapies in oncology, build personalized reports and engage with a community of healthcare professionals.
Given the expertise of OncoDNA in delivering solutions in precision medicine, we initiated this collaboration with enthusiasm with the aim of developing a specific SOLTI OncoKDM solution integrating any kind of molecular data that might reveal unappreciated vulnerabilities in the tumours of AGATA patients, allowing us to tailor much better their treatment options.
Compared to its competitors, OncoKDM includes patient-centred features that enable oncologists to recommend and make the right treatment decisions according to patient's data and medical history. Moreover, OncoKDM is user-friendly and easy to use, another advantage!